
Research suggesting semaglutide and other GLP-1 drugs may reduce addiction risk points to important effects on brain reward circuitry, while reports of emotional blunting show neurobehavioral effects can be complex. A new study reporting a possible reduction in breast cancer risk adds to a pattern of unexpected, potentially beneficial effects outside glucose and weight control, emphasizing the pleiotropic nature of these drugs. Future studies should compare mechanisms, effectiveness, and safety across different uses and identify who benefits most.
Click a connection line between nodes to view confidence and evidence.